Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
Identifieur interne : 000673 ( PubMed/Corpus ); précédent : 000672; suivant : 000674Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
Auteurs : Michael S. Okun ; Daniel WeintraubSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- drug effects : Intestines.
- etiology : Impulse Control Disorders.
- physiology : Intestines.
- therapy : Impulse Control Disorders, Parkinson Disease.
- Deep Brain Stimulation, Humans.
DOI: 10.1002/mds.25735
PubMed: 24243803
Links to Exploration step
pubmed:24243803Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?</title>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name>
<affiliation><nlm:affiliation>University of Florida Center for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, Gainesville, Florida.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="doi">10.1002/mds.25735</idno>
<idno type="RBID">pubmed:24243803</idno>
<idno type="pmid">24243803</idno>
<idno type="wicri:Area/PubMed/Corpus">000673</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?</title>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name>
<affiliation><nlm:affiliation>University of Florida Center for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, Gainesville, Florida.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Deep Brain Stimulation</term>
<term>Humans</term>
<term>Impulse Control Disorders (etiology)</term>
<term>Impulse Control Disorders (therapy)</term>
<term>Intestines (drug effects)</term>
<term>Intestines (physiology)</term>
<term>Levodopa (adverse effects)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Intestines</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Impulse Control Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Intestines</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Impulse Control Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Deep Brain Stimulation</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24243803</PMID>
<DateCreated><Year>2013</Year>
<Month>12</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>28</Volume>
<Issue>14</Issue>
<PubDate><Year>2013</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?</ArticleTitle>
<Pagination><MedlinePgn>1915-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25735</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okun</LastName>
<ForeName>Michael S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo><Affiliation>University of Florida Center for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, Gainesville, Florida.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weintraub</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>K23 NS044997</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>11</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Aug;20(8):1052-5</RefSource>
<PMID Version="1">15858803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Psychiatry. 2014 Feb;19(2):145-6</RefSource>
<PMID Version="1">23337942</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2007 Aug;13(6):369-71</RefSource>
<PMID Version="1">17049455</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2007 Nov 23;318(5854):1309-12</RefSource>
<PMID Version="1">17962524</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Fortschr Neurol Psychiatr. 2008 Jul;76(7):396-401</RefSource>
<PMID Version="1">18604773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 Oct;131(Pt 10):2720-8</RefSource>
<PMID Version="1">18941146</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2008 Dec;64 Suppl 2:S93-100</RefSource>
<PMID Version="1">19127573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CNS Drugs. 2009;23(2):157-70</RefSource>
<PMID Version="1">19173374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2009 Apr;16(4):493-7</RefSource>
<PMID Version="1">19236471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 May;132(Pt 5):1376-85</RefSource>
<PMID Version="1">19346328</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 May;65(5):586-95</RefSource>
<PMID Version="1">19288469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Aug 15;24(11):1561-70</RefSource>
<PMID Version="1">19526584</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Postgrad Med J. 2009 Nov;85(1009):590-6</RefSource>
<PMID Version="1">19892894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2009 Dec;8(12):1140-9</RefSource>
<PMID Version="1">19909912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Dec;66(6):817-24</RefSource>
<PMID Version="1">20035509</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 Jan;67(1):58-63</RefSource>
<PMID Version="1">20065130</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S111-5</RefSource>
<PMID Version="1">20123548</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuron. 2010 Jan 14;65(1):135-42</RefSource>
<PMID Version="1">20152119</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 May;67(5):589-95</RefSource>
<PMID Version="1">20457959</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jun 3;362(22):2077-91</RefSource>
<PMID Version="1">20519680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurosurg Focus. 2010 Aug;29(2):E12</RefSource>
<PMID Version="1">20672914</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Aug 15;25(11):1660-9</RefSource>
<PMID Version="1">20589879</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Sep;68(3):400-4</RefSource>
<PMID Version="1">20687121</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Oct 30;25(14):2449-53</RefSource>
<PMID Version="1">20976739</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 Jan;134(Pt 1):36-49</RefSource>
<PMID Version="1">21059746</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Dec;68(6):963-8</RefSource>
<PMID Version="1">21154480</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):56-62</RefSource>
<PMID Version="1">21304139</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Feb 1;26(2):225-33</RefSource>
<PMID Version="1">21284039</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 Apr;134(Pt 4):969-78</RefSource>
<PMID Version="1">21349901</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 May;134(Pt 5):1438-46</RefSource>
<PMID Version="1">21596771</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Addict Biol. 2011 Oct;16(4):620-3</RefSource>
<PMID Version="1">21762290</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Struct Funct. 2011 Nov;216(4):289-99</RefSource>
<PMID Version="1">21541715</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurodegener Dis. 2012;9(1):18-24</RefSource>
<PMID Version="1">21778695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S80-4</RefSource>
<PMID Version="1">22166463</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Neurochir (Wien). 2011 Dec;153(12):2293-306</RefSource>
<PMID Version="1">21976235</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2012 Jan;18(1):10-6</RefSource>
<PMID Version="1">21920794</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(1):e29768</RefSource>
<PMID Version="1">22295068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2012 May;135(Pt 5):1463-77</RefSource>
<PMID Version="1">22508959</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(5):e36572</RefSource>
<PMID Version="1">22629317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurodegener Dis. 2013;11(2):63-71</RefSource>
<PMID Version="1">23038208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Feb 26;80(9):792-9</RefSource>
<PMID Version="1">23325911</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Drug Alcohol Depend. 2013 Apr 1;129(1-2):70-81</RefSource>
<PMID Version="1">23062870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2013 Apr 24;33(17):7122-9</RefSource>
<PMID Version="1">23616522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Neurosci. 2013 Jul;20(7):964-9</RefSource>
<PMID Version="1">23712053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):868-74</RefSource>
<PMID Version="1">23447648</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Dec;28(14):2007-10</RefSource>
<PMID Version="1">24123193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Neurol Neurosci Rep. 2007 Jul;7(4):278-89</RefSource>
<PMID Version="1">17618533</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D046690">Deep Brain Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007174">Impulse Control Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007422">Intestines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS535206</OtherID>
<OtherID Source="NLM">PMC3859686</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>8</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>10</Month>
<Day>6</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>10</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year>
<Month>11</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.25735</ArticleId>
<ArticleId IdType="pubmed">24243803</ArticleId>
<ArticleId IdType="pmc">PMC3859686</ArticleId>
<ArticleId IdType="mid">NIHMS535206</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000673 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000673 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:24243803 |texte= Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24243803" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |